Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07703475 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine

StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date pushed from Sep 5, 2026 to Sep 26, 2026
  2. Re-verified, no change to tracked fields
  3. Re-verified, no change to tracked fields
  4. Start date pushed from Aug 15, 2026 to Sep 5, 2026 Eligibility criteria expanded, about 23 words · Study description revised · Site details revised at 1 of 4 sites Show 3 more changesShow less
    • Eligibility criteria expanded, about 23 words
    • Study description revised
    • Site details revised at 1 of 4 sites
  5. 3 versions Re-verified since Aug 27, 2026, no change to tracked fieldsv8-v10
Show 3 earlier versionsHide 3 earlier versions
  1. Site contacts updated at 4 of 4 sitesv7
  2. 2 versions Re-verified since Aug 6, 2026, no change to tracked fieldsv5-v6
  1. Trial sites expanded: 0 → 4 locationsv4
  2. 2 versions Re-verified since Jul 16, 2026, no change to tracked fieldsv2-v3
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of RVX-sCPD9, given Intranasally (IN), as a booster dose to previously vaccinated healthy adults. The study is designed as a non-randomized, open-label, dose-escalation clinical trial evaluating four dose levels of RVX-sCPD9 administered IN (10\^2, 10\^3, 10\^4, 5 x 10\^4 FFU). A sample size of 80 participants (20 participants in each cohort). The primary objective is to evaluate the safety and reactogenicity of a single IN administration of 4 ascending dosages of RVX-sCPD9 in previously vaccinated healthy adults.
Trial Details
NCT Number NCT07703475
Lead Sponsor National Institute of Allergy and Infectious Diseases (NIAID)
Conditions COVID -19
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov